All News
ACR20 – Day 1 Report
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Read Article
ACPA+ RA should likely NOT taper bDMARDs as less Bio survival if ACPA+ &/or monoRx. Should EULAR guidelines be changed? What about retention with JAKis? #ACR20 @RheumNow @CRASCRRheum abstr804 https://t.co/vjzIIgVJ0s
Janet Pope Janetbirdope ( View Tweet)
Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk
Eric Dein ejdein1 ( View Tweet)
CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC
Dr. Rachel Tate uptoTate ( View Tweet)
In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic remission. Other factors were dse duration<5yrs, pred<5mg/d & time-integrated DAS28ESR. @RheumNow #ACR20 abs0754 https://t.co/u0pgAsK4UX
sheila RHEUMarampa ( View Tweet)
Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug.
#RheumTwitter #lupus
Abs#0849 #ACR20 @RheumNow
https://t.co/8a6OcZmOso
Mrinalini Dey DrMiniDey ( View Tweet)
The development of biologics started with diphtheria- history of Medicine! Look how far we have come now prescribing over 50 different types of biologics! @RheumNow #acr20 https://t.co/XbygK5g7ON
alexa meara lexmeara ( View Tweet)
Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs
Janet Pope Janetbirdope ( View Tweet)
Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj
Janet Pope Janetbirdope ( View Tweet)
Great job by @Rheumnow's Dr. Jonathan Kay on CT-P17, ADA biosimilar in Abst#0800. Similar ACR20 83% rate for ADA and CT-P17 with similar safety profile. #ACR20.
Eric Dein ejdein1 ( View Tweet)
What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20
sheila RHEUMarampa ( View Tweet)
Serial RF titers? Abst#0754 from Japan: Pts with RF>45, tracked RF at month 0/4/12 after starting b/tsDMARD. 46/130 had RF decrease titers, had better radiographic remission/DAS28-ESR. Limits: varied Rx, More aggressive Rx w RF decrease grp @RheumNow. #ACR20
Eric Dein ejdein1 ( View Tweet)
Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7
Eric Dein ejdein1 ( View Tweet)
Get the highlights on the opening day of #ACR20. Listen in to faculty reports and overviews. Follow the link below or find us on Apple podcasts under RheumNow Podcast.
https://t.co/qDQzCAHsHi https://t.co/9nM19ZdHQQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
sheila RHEUMarampa ( View Tweet)
Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
Can we learn lessons about collaborative work from @rheum_covid?
Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
David Liew drdavidliew ( View Tweet)
Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant improvements in symptoms of peripheral arthritis in pts with AS. Significant improvements were seen in both tender and swollen joints @RheumNow #ACR20 Abstr#366
Dr. Antoni Chan synovialjoints ( View Tweet)
If TCZ blunts CRP a lot/ESR a fair bit, how can we pick GCA relapses in pts on TCZ?
Cool tech (mass spec w tandem mass tag multiplex) on GiACTA samples. Of 344 candidate proteins, guess what ranked highest?
Haptoglobin.
Let's validate!
@MGHrheumatology #ACR20 ABST0513 @RheumNow https://t.co/ErmqZuf2iu
David Liew drdavidliew ( View Tweet)
Better outcomes (ASAS20 and ASAS40 @wk 52) seen in younger pts (possibly lower disease duration) when Secukinumab was given to ankylosing spondylitis pts. Early Dx in #AS! #ACR20 Abstr#0350 https://t.co/EKks0b1upc https://t.co/bxIH9lloI1
Dr. John Cush RheumNow ( View Tweet)
Still more interesting lessons from GiACTA, this time re: nature of GCA flares on TCZ:
- visual manifestation flares were rare
- ESR or CRP raised in 3/4 of flares (so not raised in 1/4)
Understanding these flares is crucial!
Unizony et al @MGHMedicine #ACR20 ABST0516 @RheumNow https://t.co/WVIitov7Ut
David Liew drdavidliew ( View Tweet)